Volume 16 | July 2024
Consideration of Possible Drug-Drug Interactions Is a Critical Step in the Treatment of Tardive Dyskinesia (TD)
This newsletter is produced by Teva Pharmaceuticals, and Dr Jain was compensated by Teva for his insights.
EXPERT COMMENTARY
Expert Commentary With Rakesh Jain, MD, MPH
Dr Jain highlights the importance of evaluating potential drug-drug interactions (DDIs) when making treatment decisions for TD. Considering, recognizing, and addressing DDIs early has become the mandate of the modern-day clinician.
Read more
Past Volumes